Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Jun 21;68(24):544-551.
doi: 10.15585/mmwr.mm6824a3.

Update: Influenza Activity in the United States During the 2018-19 Season and Composition of the 2019-20 Influenza Vaccine

Xiyan Xu  1 , Lenee Blanton  1 , Anwar Isa Abd Elal  1 , Noreen Alabi  1 , John Barnes  1 , Matthew Biggerstaff  1 , Lynnette Brammer  1 , Alicia P Budd  1 , Erin Burns  1 , Charisse N Cummings  1 , Shikha Garg  1 , Rebecca Kondor  1 , Larisa Gubareva  1 , Krista Kniss  1 , Sankan Nyanseor  1 , Alissa O'Halloran  1 , Melissa Rolfes  1 , Wendy Sessions  1 , Vivien G Dugan  1 , Alicia M Fry  1 , David E Wentworth  1 , James Stevens  1 , Daniel Jernigan  1
Affiliations

Update: Influenza Activity in the United States During the 2018-19 Season and Composition of the 2019-20 Influenza Vaccine

Xiyan Xu et al. MMWR Morb Mortal Wkly Rep. .

Abstract

Influenza activity* in the United States during the 2018-19 season (September 30, 2018-May 18, 2019) was of moderate severity (1). Nationally, influenza-like illness (ILI)† activity began increasing in November, peaked during mid-February, and returned to below baseline in mid-April; the season lasted 21 weeks,§ making it the longest season in 10 years. Illness attributed to influenza A viruses predominated, with very little influenza B activity. Two waves of influenza A were notable during this extended season: influenza A(H1N1)pdm09 viruses from October 2018 to mid-February 2019 and influenza A(H3N2) viruses from February through May 2019. Compared with the 2017-18 influenza season, rates of hospitalization this season were lower for adults, but were similar for children. Although influenza activity is currently below surveillance baselines, testing for seasonal influenza viruses and monitoring for novel influenza A virus infections should continue year-round. Receiving a seasonal influenza vaccine each year remains the best way to protect against seasonal influenza and its potentially severe consequences.

PubMed Disclaimer

Conflict of interest statement

All authors have completed and submitted the ICMJE form for disclosure of potential conflicts of interest. No potential conflicts of interest were disclosed.

Figures

FIGURE 1
FIGURE 1
Number of respiratory specimens testing positive for influenza reported to CDC by public health laboratories, by influenza virus type, subtype, and surveillance week – United States, September 30, 2018–May 18, 2019 * N = 40,674. † 1,629 influenza A viruses not subtyped are excluded. § As of June 14, 2019.
FIGURE 2
FIGURE 2
Percentage of outpatient visits for influenza-like illness (ILI) reported to CDC, by surveillance week — U.S. Outpatient Influenza-like Illness Surveillance Network, 2018–19 influenza season and selected previous influenza seasons * Defined as fever (temperature of ≥100°F [≥37.8°C], oral or equivalent) and cough or sore throat, without a known cause other than influenza. † As of June 14, 2019.
See this image and copyright information in PMC

References

    1. Biggerstaff M, Kniss K, Jernigan DB, et al. Systematic assessment of multiple routine and near real-time indicators to classify the severity of influenza seasons and pandemics in the United States, 2003–2004 through 2015–2016. Am J Epidemiol 2018;187:1040–50. 10.1093/aje/kwx334 - DOI - PMC - PubMed
    1. World Health Organization. Laboratory methodologies for testing the antiviral susceptibility of influenza viruses: neuraminidase inhibitor (NAI). Geneva, Switzerland: World Health Organization; 2019. https://www.who.int/influenza/gisrs_laboratory/antiviral_susceptibility/...
    1. Gubareva LV, Mishin VP, Patel MC, et al. Assessing baloxavir susceptibility of influenza viruses circulating in the United States during the 2016/17 and 2017/18 seasons. Euro Surveill 2019;24. 10.2807/1560-7917.ES.2019.24.3.1800666 - DOI - PMC - PubMed
    1. World Health Organization. Recommended composition of influenza virus vaccines for use in the 2019–2020 northern hemisphere influenza season. Geneva, Switzerland: World Health Organization; 2019. https://www.who.int/influenza/vaccines/virus/recommendations/2019_20_nor...
    1. Food and Drug Administration Center for Biologics Evaluation and Research. Vaccines and Related Biological Products Advisory Committee meeting announcement, March 6–7, 2019. Silver Spring, MD: Department of Health and Human Services, Food and Drug Administration; 2019. https://www.fda.gov/advisory-committees/advisory-committee-calendar/vacc...

MeSH terms